Recombinant Cynomolgus B7-H7/HHLA2 His-tag Protein, CF

When Recombinant Human TMIGD2/CD28H Fc Chimera (Catalog # 8316-TR) is coated at 2 μg/mL (100 μL/well), Recombinant Cynomolgus B7-H7/HHLA2 (Catalog # 10109-B7) binds with an ED50 of 0.2‑1.2 μg/mL

2 μg/lane of Recombinant Cynomolgus Monkey B7-H7/HHLA2 (Catalog#10109-B7) was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 62-70 kDa.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus B7-H7/HHLA2 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Human TMIGD2/CD28H Fc Chimera (Catalog # 8316-TR) is immobilized at 1 µg/mL (100 µL/well), the concentration of Recombinant Cynomolgus Monkey B7-H7/HHLA2 (Catalog#10109-B7)that produces 50% of the optimal binding response is 0.2-1.2 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived cynomolgus monkey B7-H7/HHLA2 protein
  Ile21-Asn345, with a C-terminal 6-His tag
• Accession #: XP_005548285
• N-terminal Sequence: Ile21
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 38 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 62-70 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus B7-H7/HHLA2 His-tag Protein, CF

• B7H7
• B7-H7
• HERV-H LTR-associating 2
• HERV-H LTR-associating protein 2
• HHLA2
• Human endogenous retrovirus-H long terminal repeat-associating protein 2

Background

B7-H7, also known as HHLA2 (HERV-H LTR-associating protein 2), is a member of the B7 family of immune regulatory proteins (1, 2). The mature human B7-H7 protein consists of a 322 amino acid (aa) extracellular domain (ECD) with three immunoglobulin-like domains, a 21 aa transmembrane segment, and a 49 aa cytoplasmic domain (3-5). Within the ECD, cynomolgus B7-H7 shares 90% aa sequence identity with human B7-H7. It is constitutively expressed on monocytes and is up-regulated by LPS and IFN-gamma stimulation. It is expressed on LPS/IFN-gamma treated B cells but not on resting B cells (5). B7-H7 binds to cell surface determinants on resting and mature T cells, B cells, and monocytes as well as on immature and mature dendritic cells (5). The receptor TMIGD2, commonly found in endothelial and epithelial cells, has also been identified as one of the receptors for B7-H7 (6). Soluble B7-H7 inhibits the proliferation of activated CD4⁺ and CD8⁺ T cells and their production of IFN-gamma, TNF-alpha, IL-5, IL-10, IL-13, IL-17A, and IL-22 (5).

1. Zou, W. and L. Chen (2008) Nat. Rev. Immunol. 8:467.
2. Bour-Jordan, H. et al. (2011) Immunol. Rev. 241:180.
3. Mager, D.L. et al. (1999) Genomics 59:255.
4. Flajnik, M.M. et al. (2012) Immunogenetics 64:571.
5. Zhao, R. et al. (2013) Proc. Natl. Acad. Sci. USA 110:9879.
6. Janakiram, M. et al. (2015) Oncoimmunology 4:8.

Bioinformatics

• Uniprot:
  • XP_005548285()